Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  The Ottawa Hospital, Ottawa, Ontario – Recruiting

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  University Health Network - Princess Margaret Cancer Center, Toronto, Ontario – Active, not recruiting

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase:
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Local Institution, Toronto, Ontario – Active, not recruiting

  Local Institute, Toronto, Ontario – Recruiting

  Local Institution, Toronto, Ontario – Terminated

  
  Other Centres
  
  

  Local Institute, Weston, Ontario – Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Center/Alberta Health Services, Calgary, Alberta – Withdrawn

  Cross Cancer Institute / University of Alberta, Edmonton, Alberta – Recruiting

  Vancouver General Hospital, Vancouver, British Columbia – Withdrawn

  
  Other Centres
  
  

  Cancer Care Manitoba, Winnipeg, Manitoba – Active, not recruiting

  Memorial Hospital of Newfoundland, St. John's, Newfoundland and Labrador – Active, not recruiting

  Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  Maisonneuve-Rosemont Hospital, Montreal, Quebec – Active, not recruiting

  Royal Victoria Hospital / McGill University, Montreal, Quebec – Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

• Condition:
  Prostatic Neoplasms
  Colorectal Neoplasms
  Multiple Myeloma
  Neoplasms, Plasma Cell
  Leukemia, Myeloid, Acute
  Preleukemia
  Myelodysplastic Syndromes
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  McMaster - Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

  Princess Margaret Cancer Center, Toronto, Ontario – Recruiting

  Princess Margaret Cancer Research, Toronto, Ontario – Completed

  
  Other Centres
  
  

  MUHC GLEN Site Cedars - Cancer Centre, Montréal, Quebec – Completed

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

• Condition:
  Leukemia
  Leukemia, Myeloid
  Multiple Myeloma
  Neoplasms, Plasma Cell
  Leukemia, Myeloid, Acute
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

  University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Local Institution - 904, Calgary, Alberta – Recruiting

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

  Vancouver General Hospital, Vancouver, British Columbia – Recruiting

  
  Other Centres
  
  

  Local Institution - 902, Halifax, Nova Scotia – Recruiting

  Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia – Recruiting

  McGill University Health Center - Royal Victoria Hospital, Montreal, Quebec – Recruiting

MMRF Molecular Profiling Protocol

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  Neoplasms
  
• Study Phase:
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Princess Margaret Cancer Centre, Toronto, Ontario – Active, not recruiting

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia – Not yet recruiting

  Juravinski Cancer Centre, Hamilton, Ontario – Not yet recruiting

  Victoria Hospital, London, Ontario – Not yet recruiting

  
  Other Centres
  
  

  Centre de Recherche du CHUM, Montreal, Quebec – Not yet recruiting

  Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec – Not yet recruiting

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  University of Calgary, Calgary, Alberta – Recruiting

  Princess Margaret Cancer Center, Toronto, Ontario – Recruiting

  Jewish General Hospital, Montreal, Quebec – Recruiting

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  McGill University Health Centre Glen Site, Montreal, Quebec – Terminated

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

• Condition:
  Multiple Myeloma
  Lymphoma, Non-Hodgkin
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Cross Cancer Institute, Edmonton, Alberta – Recruiting

  BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia – Suspended

  BCCA - Vancouver Cancer Centre, Vancouver, British Columbia – Recruiting

  
  Other Centres
  
  

  Kingston Health Sciences Centre, Kingston, Ontario – Recruiting

  London Regional Cancer Program, London, Ontario – Recruiting

  Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting

  University Health Network, Toronto, Ontario – Recruiting

  The Jewish General Hospital, Montreal, Quebec – Recruiting

  Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

  Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Local Institution - 201, Calgary, Alberta – Recruiting

  Tom Baker Cancer Center, Calgary, Alberta – Recruiting

  Local Institution - 204, London, Ontario – Recruiting

  
  Other Centres
  
  

  London Health Sciences Centre, London, Ontario – Recruiting

  Local Institution - 205, Ottawa, Ontario – Recruiting

  Ottawa General Hospital, Ottawa, Ontario – Recruiting

  Local Institution - 202, Toronto, Ontario – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  Local Institution - 206, Montreal, Quebec – Recruiting

  McGill, Montreal, Quebec – Recruiting

  CHUQ, Quebec, – Recruiting

  Local Institution - 203, Quebec, – Recruiting

Multiple Myeloma Molecular Monitoring Study

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase:
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

  Cross Cancer Institute, Edmonton, Alberta – Recruiting

  Vancouver General Hospital, Vancouver, British Columbia – Recruiting

  
  Other Centres
  
  

  CancerCare Manitoba, Winnipeg, Manitoba – Recruiting

  Saint John Regional Hospital (Horizon Health Network), Saint John, New Brunswick – Recruiting

  Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia – Recruiting

  Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

  The Ottawa Hospital, Ottawa, Ontario – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  CIUSSS de l'Est-de-l'Île-de-Montréal (Maisonneuve-Rosemount), Montréal, Quebec – Withdrawn

  McGill University Health Centre, Montréal, Quebec – Recruiting

  Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

  Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2/Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  London Health Sciences Centre, London, Ontario – Recruiting

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Local Institution - 302, Calgary, Alberta – Active, not recruiting

  Tom Baker Cancer center, Calgary, Alberta – Active, not recruiting

  Local Institution - 303, Toronto, Ontario – Active, not recruiting

  
  Other Centres
  
  

  Princess Margaret Cancer Centre, Toronto, Ontario – Active, not recruiting

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

• Condition:
  Meningioma
  Colorectal Neoplasms, Hereditary Nonpolyposis
  Uterine Neoplasms
  Hamartoma Syndrome, Multiple
  Syndrome
  
• Study Phase:
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Cross Cancer Institute, Edmonton, Alberta – Recruiting

  Vancouver General Hospital, Vancouver, British Columbia – Recruiting

  CancerCare Manitoba, Winnipeg, Manitoba – Recruiting

  
  Other Centres
  
  

  QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting

  Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

  London Health Sciences Centre, London, Ontario – Recruiting

  The Ottawa Hospital, Ottawa, Ontario – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  Neoplasm, Residual
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Princess Margaret Hospital, Toronto, Ontario – Recruiting

  McGill University Health Centre, Montreal, Quebec – Recruiting

  CHU de Québec-Université Laval-Hôpital de l'Enfant-Jésus, Quebec, – Recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Princess Margaret Hospital, Toronto, Ontario – Recruiting

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

• Condition:
  Multiple Myeloma
  Amyloidosis
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Local Institution - 201, Calgary, Alberta – Recruiting

  Tom Baker Cancer Center, Calgary, Alberta – Recruiting

  University of Alberta - Faculty of Medicine and Dentistry, Edmonton, Alberta – Recruiting

  
  Other Centres
  
  

  Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec – Recruiting

Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients

• Condition:
  Hematologic Neoplasms
  
• Study Phase: N/A
• Recruitment Status: Recruiting

• Nearest Centres:
  

  London Health Sciences Centre-Victoria Hospital, London, Ontario – Recruiting

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Center, Calgary, Alberta – Not yet recruiting

  Local Institution - 202, Toronto, Ontario – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  
  Other Centres
  
  

  Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec – Recruiting

  Local Institution - 201, Montreal, Quebec – Recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  GSK Investigational Site, Edmonton, Alberta – Recruiting

  GSK Investigational Site, London, Ontario – Completed

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

  Vancouver General Hospital, Vancouver, British Columbia – Withdrawn

  University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  GSK Investigational Site, Vancouver, British Columbia – Recruiting

  GSK Investigational Site, Halifax, Nova Scotia – Recruiting

  GSK Investigational Site, Toronto, Ontario – Recruiting

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  CancerCare Manitoba, Winnipeg, Manitoba – Recruiting

  The Moncton Hospital, Moncton, New Brunswick – Recruiting

  CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec – Recruiting

  
  Other Centres
  
  

  Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  Smoldering Multiple Myeloma
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Investigational Site Number :1240004, Edmonton, Alberta – Recruiting

  Investigational Site Number :1240005, Moncton, New Brunswick – Recruiting

  Investigational Site Number :1240001, Montreal, Quebec – Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  GSK Investigational Site, Ottawa, Ontario – Recruiting

  GSK Investigational Site, Toronto, Ontario – Recruiting

  GSK Investigational Site, Montreal, – Recruiting

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Hematologic Neoplasms
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Active, not recruiting

  Cross Cancer Institute, Edmonton, Alberta – Active, not recruiting

  University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario – Active, not recruiting

  
  Other Centres
  
  

  McGill University Health Centre, Montreal, Quebec – Completed

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Alberta Health Services, Edmonton, Alberta – Recruiting

  McGill University Health Centre, Montreal, Quebec – Recruiting

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase:
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Cross Cancer Institute /ID# 224172, Edmonton, Alberta – Recruiting

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Cross Cancer Institute, Edmonton, Alberta – Not yet recruiting

  CancerCare Manitoba, Winnipeg, Manitoba – Not yet recruiting

  Eastern Health - Health Sciences Centre, Saint John's, Newfoundland and Labrador – Not yet recruiting

  
  Other Centres
  
  

  Nova Scotia Health - QEII Health Sciences Centre, Halifax, Nova Scotia – Not yet recruiting

  Hamilton Health Sciences Centre, Hamilton, Ontario – Recruiting

  The Ottawa Hospital General Campus, Ottawa, Ontario – Recruiting

  Health Sciences North, Sudbury, Ontario – Not yet recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

  Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

  Saskatoon Cancer Center, Saskatoon, Saskatchewan – Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario – Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

  Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

  Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Recruiting

  
  Other Centres
  
  

  Hopital Maisonneuve-Rosemont, Montréal, Quebec – Recruiting

  Vancouver General Hospital, Vancouver, – Recruiting

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  British Columbia Cancer Center, Vancouver, British Columbia – Not yet recruiting

  University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario – Not yet recruiting

  CIUSSS de l'Est de-L'Île-de-Montréal installation Hôpital Maisonneuve-Rosemont, Montréal, Quebec – Not yet recruiting

  
  Other Centres
  
  

  Jewish General Hospital, Montréal, Quebec – Not yet recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Center, Calgary, Alberta – Recruiting

  Cross Cancer Institute, Edmonton, Alberta – Not yet recruiting

  Dalhousie University, Halifax, Nova Scotia – Not yet recruiting

  
  Other Centres
  
  

  Princess Margaret Hospital University Health Network, Toronto, Ontario – Recruiting

  McGill University Health Center (MUHC), Montreal, Quebec – Not yet recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Not yet recruiting

  Cross Cancer Institute, Edmonton, Alberta – Not yet recruiting

  BC Cancer Agency, Fraser Valley Center, Surrey, British Columbia – Not yet recruiting

  
  Other Centres
  
  

  Saint John Regional Hospital, Saint John, New Brunswick – Not yet recruiting

  Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador – Not yet recruiting

  Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia – Not yet recruiting

  Hamilton Health Sciences Corporation, Hamilton, Ontario – Not yet recruiting

  Local Institution - 113, Toronto, Ontario – Not yet recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Not yet recruiting

  Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec – Not yet recruiting

  The Ottawa Hospital - General Campus, Ottawa, Quebec – Not yet recruiting

  University of Saskatchewan, Saskatoon, Saskatchewan – Not yet recruiting

  CHUQ, Quebec, – Not yet recruiting

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Center, Calgary, Alberta – Recruiting

  Cross Cancer Institute, Edmonton, Alberta – Not yet recruiting

  QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Recruiting

  
  Other Centres
  
  

  Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia – Recruiting

  Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  GSK Investigational Site, Oshawa, Ontario – Recruiting

  GSK Investigational Site, Montreal, Quebec – Recruiting

  GSK Investigational Site, Montréal, Quebec – Recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

  Cross Cancer Institute, Edmonton, Alberta – Recruiting

  BC Cancer Agency - Vancouver BC, Vancouver, British Columbia – Recruiting

  
  Other Centres
  
  

  Qwii Health Sciences, Halifax, Nova Scotia – Recruiting

  Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Recruiting

  McGill University Health Centre, Montreal, Quebec – Withdrawn

  CHU de Québec, Quebec, – Withdrawn

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Center, Calgary, Alberta – Not yet recruiting

  The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting

  Princess Margaret Cancer Centre, Toronto, Ontario – Not yet recruiting

Early Integration of Palliative and Supportive Care in Hematopoietic Stem Cell Transplantation

• Condition:
  Multiple Myeloma
  Hematologic Neoplasms
  
• Study Phase: N/A
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – Not yet recruiting

  Tom Baker Cancer Center, Calgary, Alberta – Not yet recruiting

  Hamilton Health Sciences Corporation, Hamilton, Ontario – Recruiting

  
  Other Centres
  
  

  Princess Margaret Cancer Centre, Toronto, Ontario – Not yet recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1/Phase 2
• Recruitment Status: Recruiting

• Nearest Centres:
  

  Local Institution - 0004, Toronto, Ontario – Not yet recruiting

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Not yet recruiting

• Nearest Centres:
  

  Nova Scotia Health Authority, Halifax, Nova Scotia – ()

  University Health Network, Toronto, Ontario – ()

  CIUSSS de l'Est-de-l'Île-de-Montréal Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec – ()

  
  Other Centres
  
  

  CHU de Québec Université Laval, Quebec, – ()

A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Not yet recruiting

• Nearest Centres:
  

  Local Institution - 0225, Greenfield Park, Quebec – ()

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Not yet recruiting

• Nearest Centres:
  

  Tom Baker Cancer Center, University of Calgary, Calgary, Alberta – ()

  Cross Cancer Institute, Edmonton, Alberta – ()

  British Columbia Cancer Agency, Vancouver, British Columbia – ()

  
  Other Centres
  
  

  Juravinski Cancer Centre, Hamilton, Ontario – ()

  The Ottawa Hospital - General Campus, Ottawa, Ontario – ()

  CHU de Québec Université Laval, Quebec, – ()

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 1
• Recruitment Status: Not yet recruiting

• Nearest Centres:
  

  University Health Network (UHN) - Princess Margaret Cancer Centre - Myeloma Clinic, Toronto, Ontario – ()

  McGill University Health Centre (MUHC) - The Montreal General Hospital (MGH) - Cedars Cancer Centre, Montreal, Quebec – ()

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

• Condition:
  Multiple Myeloma
  Neoplasms, Plasma Cell
  
• Study Phase: Phase 3
• Recruitment Status: Not yet recruiting

• Nearest Centres:
  

  Tom Baker Cancer Centre, Calgary, Alberta – ()

  Nova Scotia Health Authority, Halifax, Nova Scotia – ()

  Juravinski Cancer Centre, Hamilton, Ontario – ()

  
  Other Centres
  
  

  Lakeridge Health Oshawa, Oshawa, Ontario – ()

  CIUSSS de l'Est-de-l'Île-de-Montréal Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec – ()